Cornea and Anterior Segment Service, LV Prasad Eye Institute, Hyderabad, Andhra Pradesh, India.
Indian J Ophthalmol. 2013 Aug;61(8):441-4. doi: 10.4103/0301-4738.116068.
The success of collagen cross-linking as a clinical modality to modify the clinical course in keratoconus seems to have fueled the search for alternative applications for this treatment. Current clinical data on its efficacy is limited and laboratory data seems to indicate that it performs poorly against resistant strains of bacteria and against slow growing organisms. However, the biological plausibility of crosslinking and the lack of effective strategies in managing infections with these organisms continue to focus attention on this potential treatment. Well-conducted experimental and clinical studies with controls are required to answer the questions of its efficacy in future.
交联技术作为一种临床手段来改变圆锥角膜的病程似乎取得了成功，这激发了人们对这种治疗方法的其他应用的探索。目前关于其疗效的临床数据有限，实验室数据似乎表明，它在对抗耐药菌株和缓慢生长的生物体方面效果不佳。然而，交联的生物学合理性以及在管理这些生物体感染方面缺乏有效的策略，使得人们继续关注这种潜在的治疗方法。需要进行有对照的良好设计的实验和临床研究，以回答其未来疗效的问题。
